9 Review of guidance

9 Review of guidance

9.1 Information on the review of the guidance on this technology is available on the NICE website

9.2 Should any significant new evidence of clinical effectiveness or a re-evaluation of published or unpublished clinical data become available, or if there were to be a substantial change in unit costs or other actions, which led to a significant change in the cost effectiveness of the beta interferons or glatiramer, this new information will be considered by the Institute. A judgement will be made at that time as to whether such evidence should result in an earlier review of this guidance.

Andrew Dillon
Chief Executive
January 2002